Biomodulina T Boosts the Immune System and Joins the Battle Against COVID-19 Infection

The National Center for Biopreparations (BIOCEN) homeopathic medication, Biomodulina^Ⓡ T, first registered in 1994 to treat compromised immune systems, is being used in Cuba’s COVID-19 battle as a preventive measure.

Cuba began using the medication almost 20 years ago for at-risk groups such as older persons with respiratory disease and in cases of chronic illness such as diabetes and cardiovascular disease.

Biomodulina T is a biological immunomodulator that supports and balances the immune system. It has demonstrated proven results in boosting the body’s natural defenses.

Dr. Mary Carmen Reyes, the head of the BIOCEN Clinical Trials Group, told the Cuban media that Biomodulina T is given to high-risk groups with compromised immune systems including seniors, health personnel, and people with suspected SARS COV-2 (COVID-19) infection.

Dr. Reyes stated that Biomodulina T is a biological immunomodulator, a natural formulation derived from extracts of bovine thymus. It stimulates the production of T-lymphocytes and strengthens the differentiation of the lymphoblastoid cells in the thymus, one of the immune system’s most important glands.

The homeopathic medication has been evaluated by US National Library of Medicine National Institutes of Health and found to partially restore immunosenescent CD4 and CD8 T cell compartments in elderly patients.

Biomodulina T is one of 22 medicines in the current COVID-19 treatment protocol. This is a process that is undergoing constantly evaluation (now on its third variant) based on experience and continuous acquisition of knowledge.

There are two different routes of administration for Biomodulina T, either via intramuscular or intravenous injection with few reports of any adverse side effects.